Druck Icon

Eckert & Ziegler: Revenue Growth, Stable Earnings

Berlin, 7 August 2007. Eckert & Ziegler Strahlen- und Medizintechnik AG (ISIN DE0005659700), a globally active specialist for radioactive applications in medicine, science and industry with a focus on cancer radiation systems and measurement technology, increased its sales revenues for the half year by 14% to 26.5 million EUR. The EBIT for the first six months of 2007 rose to 2.9 million EUR (+14%), net income however remained at 0.46 EUR per share (previous half year: 0.45 EUR) due to tax adjustments and a lower income contribution from low tax countries.

The Radiopharmaceutical segment showed the strongest growth in the half year with an increase in sales of 30% over last year's period, to 3.1 million EUR. Sales in the Therapy segment rose by 19% to 10.4 million EUR. Due to outstanding developments in industrial products and raw isotopes, sales in the Nuclear Imaging and Industry segment grew by 8% to 12.9 million EUR, despite the unfavorable progression of the exchange rate with the dollar.

The development shown by the business year thus far meets the expectations of the Board, with the result that the Board continues to anticipate a result of 2.8 million EUR (0.90 EUR per share) before special and one-time effects for the 2007 business year. Due to the 2008 German corporate tax reform, however, a non-monetary burden of 0.8 million EUR (0.25 EUR per share) is expected. Further details on the interim results will be provided in the quarterly report to be released today.

The Board of Directors